Positive News SentimentPositive NewsNASDAQ:AVTX Avalo Therapeutics (AVTX) Stock Forecast, Price & News $4.02 -0.13 (-3.13%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$4.01▼$4.3850-Day Range$1.80▼$4.1552-Week Range$1.41▼$7.41Volume27,143 shsAverage Volume48,266 shsMarket Capitalization$53.06 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Avalo Therapeutics MarketRank™ ForecastAnalyst RatingReduce1.00 Rating ScoreUpside/Downside285.6% Upside$15.50 Price TargetShort InterestHealthy0.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$309,678 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.13) to ($2.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector586th out of 988 stocksPharmaceutical Preparations Industry272nd out of 480 stocks 2.5 Analyst's Opinion Consensus RatingAvalo Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.50, Avalo Therapeutics has a forecasted upside of 285.6% from its current price of $4.02.Amount of Analyst CoverageAvalo Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.42% of the float of Avalo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalo Therapeutics has recently increased by 17.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvalo Therapeutics does not currently pay a dividend.Dividend GrowthAvalo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVTX. Previous Next 2.7 News and Social Media Coverage News SentimentAvalo Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Avalo Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for AVTX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avalo Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $309,678.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders45.40% of the stock of Avalo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.46% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avalo Therapeutics are expected to grow in the coming year, from ($3.13) to ($2.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avalo Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avalo Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Avalo Therapeutics (NASDAQ:AVTX) StockAvalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Read More Receive AVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTX Stock News HeadlinesJune 1, 2023 | finance.yahoo.comAvalo to Present at the Jefferies Healthcare ConferenceMay 24, 2023 | americanbankingnews.comCaissa Capital Management Ltd. Buys 7,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) StockJune 10, 2023 | Behind the Markets (Ad)AI Creates New Cancer Drug - In Just 30 Days!On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...May 24, 2023 | americanbankingnews.comCaissa Capital Management Ltd. Buys 13,121 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) StockMay 22, 2023 | finance.yahoo.comAvalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory BoardMay 18, 2023 | finanznachrichten.deAvalo Therapeutics: Avalo Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 17, 2023 | benzinga.comChief Financial Officer at Avalo Therapeutics Acquires Company Stock Options Worth 40,000 SharesMay 15, 2023 | finance.yahoo.comAvalo to Present at ATS 2023 Respiratory Innovation SummitJune 10, 2023 | Behind the Markets (Ad)AI Creates New Cancer Drug - In Just 30 Days!On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...May 11, 2023 | americanbankingnews.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Major Shareholder Caissa Capital Management Ltd. Purchases 15,000 SharesMay 10, 2023 | finance.yahoo.comAvalo to Present at the 2023 RBC Capital Markets Global Healthcare ConferenceMay 10, 2023 | americanbankingnews.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Major Shareholder Caissa Capital Management Ltd. Purchases 5,000 SharesMay 6, 2023 | seekingalpha.comAvalo Therapeutics GAAP EPS of -$0.85, revenue of $0.48MMay 5, 2023 | americanbankingnews.comMedicure (OTCMKTS:MCUJF) vs. Avalo Therapeutics (NASDAQ:AVTX) Financial ComparisonMay 4, 2023 | msn.comAvalo Therapeutics, Inc. (AVTX) Reports Q1 Loss, Lags Revenue EstimatesMay 4, 2023 | finance.yahoo.comAvalo Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 1, 2023 | americanbankingnews.comReviewing Avalo Therapeutics (NASDAQ:AVTX) & Provention Bio (NASDAQ:PRVB)April 27, 2023 | americanbankingnews.comInsider Buying: Avalo Therapeutics, Inc. (NASDAQ:AVTX) Major Shareholder Purchases 12,500 Shares of StockApril 21, 2023 | americanbankingnews.comInsider Buying: Avalo Therapeutics, Inc. (NASDAQ:AVTX) Major Shareholder Purchases $44,400.00 in StockApril 13, 2023 | finance.yahoo.comCambyz Golestaneh Just Bought 4.0% More Shares In Avalo Therapeutics, Inc. (NASDAQ:AVTX)April 13, 2023 | americanbankingnews.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Major Shareholder Caissa Capital Management Ltd. Acquires 31,329 SharesApril 13, 2023 | americanbankingnews.comReviewing Avalo Therapeutics (AVTX) and Its RivalsApril 4, 2023 | americanbankingnews.comOppenheimer Weighs in on Avalo Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:AVTX)April 3, 2023 | benzinga.comDo Analysts Expect Avalo Therapeutics Inc (AVTX) Stock to Rise After It Is Down -34.07% in a Month?April 1, 2023 | americanbankingnews.comShort Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Declines By 24.6%March 29, 2023 | finanznachrichten.deAvalo Therapeutics: Avalo Reports 2022 Financial Results and Provides Business UpdatesMarch 29, 2023 | finance.yahoo.comAvalo Reports 2022 Financial Results and Provides Business UpdatesSee More Headlines AVTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVTX Company Calendar Last Earnings3/29/2023Today6/10/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVTX CUSIPN/A CIK1534120 Webwww.avalotx.com Phone(410) 522-8707FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.50 High Stock Price Forecast$21.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+285.6%Consensus RatingReduce Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,660,000.00 Net Margins-170.36% Pretax Margin-170.20% Return on Equity-950.78% Return on Assets-85.46% Debt Debt-to-Equity RatioN/A Current Ratio0.83 Quick Ratio0.83 Sales & Book Value Annual Sales$18.05 million Price / Sales2.94 Cash FlowN/A Price / Cash FlowN/A Book Value($1.16) per share Price / Book-3.47Miscellaneous Outstanding Shares13,200,000Free Float7,208,000Market Cap$53.06 million OptionableOptionable Beta1.62 Key ExecutivesDr. Garry A. Neil M.D. (Age 69)Chairman, Pres & CEO Comp: $601.9kMr. Christopher Ryan Sullivan (Age 39)CFO & Head of Investor relations Comp: $466.94kDr. Solomon H. Snyder M.D. (Age 84)Founder and Chairman of Scientific Advisory Board Dr. Barbara S. Slusher Ph.D. (Age 58)Founder and Member of Scientific Advisory Board Dr. Lisa Hegg Ph.D.Sr. VP of Program Management, Corp. Infrastructure & Clinical OperationsMs. Colleen MatkowskiSr. VP of Global Regulatory Affairs & Quality AssuranceDr. Dino C. Miano Ph.D.Sr. VP of CMC & Technical OperationsMore ExecutivesKey CompetitorsMinerva NeurosciencesNASDAQ:NERVAchilles TherapeuticsNASDAQ:ACHLSynlogicNASDAQ:SYBXSenti BiosciencesNASDAQ:SNTISoleno TherapeuticsNASDAQ:SLNOView All CompetitorsInsiders & InstitutionsCaissa Capital Management Ltd.Bought 671 shares on 5/30/2023Total: $1,925.77 ($2.87/share)Caissa Capital Management Ltd.Bought 2,000 shares on 5/25/2023Total: $5,540.00 ($2.77/share)Caissa Capital Management Ltd.Bought 7,000 shares on 5/22/2023Total: $23,380.00 ($3.34/share)Caissa Capital Management Ltd.Bought 13,121 shares on 5/18/2023Total: $43,168.09 ($3.29/share)Armistice Capital LLCBought 450,334 shares on 5/16/2023Ownership: 33.444%View All Insider TransactionsView All Institutional Transactions AVTX Stock - Frequently Asked Questions Should I buy or sell Avalo Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" AVTX shares. View AVTX analyst ratings or view top-rated stocks. What is Avalo Therapeutics' stock price forecast for 2023? 1 brokers have issued 12 month target prices for Avalo Therapeutics' stock. Their AVTX share price forecasts range from $10.00 to $21.00. On average, they predict the company's stock price to reach $15.50 in the next year. This suggests a possible upside of 285.6% from the stock's current price. View analysts price targets for AVTX or view top-rated stocks among Wall Street analysts. How have AVTX shares performed in 2023? Avalo Therapeutics' stock was trading at $5.0401 at the beginning of the year. Since then, AVTX stock has decreased by 20.2% and is now trading at $4.02. View the best growth stocks for 2023 here. When is Avalo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our AVTX earnings forecast. How were Avalo Therapeutics' earnings last quarter? Avalo Therapeutics, Inc. (NASDAQ:AVTX) released its earnings results on Wednesday, March, 29th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by $0.52. The firm earned $0.90 million during the quarter, compared to analyst estimates of $5.20 million. Avalo Therapeutics had a negative trailing twelve-month return on equity of 950.78% and a negative net margin of 170.36%. When did Avalo Therapeutics' stock split? Shares of Avalo Therapeutics reverse split before market open on Friday, July 8th 2022. The 1-12 reverse split was announced on Friday, July 8th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 8th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Avalo Therapeutics' stock symbol? Avalo Therapeutics trades on the NASDAQ under the ticker symbol "AVTX." Who are Avalo Therapeutics' major shareholders? Avalo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (33.44%), Great Point Partners LLC (3.60%), Alyeska Investment Group L.P. (3.03%), Braidwell LP (1.87%) and Monashee Investment Management LLC (0.45%). Insiders that own company stock include Armistice Capital, Llc, Caissa Capital Management Ltd, Christopher Ryan Sullivan, Garry Arthur Neil, H Jeffrey Wilkins and Schond L Greenway. View institutional ownership trends. How do I buy shares of Avalo Therapeutics? Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avalo Therapeutics' stock price today? One share of AVTX stock can currently be purchased for approximately $4.02. How much money does Avalo Therapeutics make? Avalo Therapeutics (NASDAQ:AVTX) has a market capitalization of $53.06 million and generates $18.05 million in revenue each year. The company earns $-41,660,000.00 in net income (profit) each year or ($2.93) on an earnings per share basis. How can I contact Avalo Therapeutics? Avalo Therapeutics' mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The official website for the company is www.avalotx.com. The company can be reached via phone at (410) 522-8707 or via email at ir@cerecor.com. This page (NASDAQ:AVTX) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.